Table 2 Univariable and multivariable Cox proportional hazard model of metastasis-free survival (MFS) and recurrence-free survival (RFS) in five pTN groups.

From: Prognostic significance of pathologic nodal positivity in non-metastatic patients with renal cell carcinoma who underwent radical or partial nephrectomy

 

MFS (n = 4236, event = 141)

RFS (n = 4236, event = 410)

Univariable model

Multivariable model

Univariable model

Multivariable model

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

Group

pT1N0

1 (ref)

 

1 (ref)

 

1 (ref)

 

1 (ref)

 

pTxN1

6.15 (2.22–17.04)

0.001

6.53 (2.3–18.56)

< .001

15.71 (10.45–23.6)

< .001

6.67 (4.06–10.94)

< .001

pT2N0

5.34 (3.38–8.45)

< .001

5.14 (3.22–8.21)

< .001

4.51 (3.42–5.94)

< .001

2.18 (1.61–2.96)

< .001

pT3N0

8.44 (5.73–12.44)

< .001

6.53 (4.37–9.76)

< .001

6.92 (5.50–8.70)

< .001

3.66 (2.81–4.76)

< .001

pT4N0

11.75 (3.66–37.75)

< .001

7.08 (2.18–22.99)

0.001

17.76 (10.09–31.25)

< .001

5.26 (2.79–9.88)

< .001

Age at operation

 

1.02 (1.01–1.04)

0.003

  

1.01 (1.00–1.02)

0.005

  

Body mass index (kg/cm2)

 

0.97 (0.92–1.02)

0.255

  

0.94 (0.91–0.97)

< .001

0.96 (0.93–0.99)

0.022

Diabetes

Yes

1.06 (0.66–1.72)

0.806

  

1.13 (0.86–1.49)

0.380

  

Hypertension

Yes

1.65 (1.18–2.31)

0.004

1.50 (1.06–2.12)

0.021

1.10 (0.90–1.34)

0.380

  

ASA

1 + 2

1 (ref)

   

1 (ref)

 

1 (ref)

 

3 + 4

1.20 (0.53–2.73)

0.667

  

2.52 (1.71–3.70)

< .001

2.21 (1.49–3.29)

< .001

Hb

Female (≤ 12), male (≤ 13)

1 (ref)

   

1 (ref)

 

1 (ref)

 

Female (> 12), male (> 13)

0.49 (0.34–0.70)

< .001

  

0.39 (0.32–0.48)

< .001

0.76 (0.60–0.96)

0.020

Platelet

≥ 150, ≤ 450

1 (ref)

 

1 (ref)

 

1 (ref)

 

1 (ref)

 

< 150

0.90 (0.42–1.93)

0.780

0.96 (0.45–2.06)

0.909

0.43 (0.22–0.83)

0.012

0.38 (0.19–0.77)

0.007

> 450

5.25 (2.44–11.3)

< .001

2.18 (1.00–4.75)

0.051

5.17 (3.21–8.33)

< .001

1.77 (1.07–2.92)

0.027

Creatinine

≤ 1.3

1 (ref)

   

1 (ref)

   

> 1.3

1.49 (0.87–2.54)

0.150

  

1.43 (1.03–1.98)

0.034

  

Albumin

≤ 3.0

1 (ref)

   

1 (ref)

   

> 3.0

0.61 (0.19–1.90)

0.391

  

0.47 (0.26–0.85)

0.013

  

Nephrectomy

Open surgery

1 (ref)

   

1 (ref)

 

1 (ref)

 

Laparoscopic

0.55 (0.38–0.79)

0.001

  

0.35 (0.28–0.44)

< .001

0.60 (0.46–0.77)

< .001

Operative extent

Partial

1 (ref)

   

1 (ref)

 

1 (ref)

 

Radical

3.30 (1.91–5.70)

< .001

  

3.72 (2.72–5.09)

< .001

1.83 (1.28–2.61)

0.001

Histology

Clear cell

1 (ref)

 

1 (ref)

 

1 (ref)

 

1 (ref)

 

Non-clear cell

0.64 (0.35–1.15)

0.134

0.45 (0.25–0.82)

0.009

0.69 (0.50–0.97)

0.030

0.52 (0.37–0.74)

< .001

Mixed

1.74 (0.43–7.03)

0.440

1.77 (0.43–7.28)

0.426

1.70 (0.76–3.81)

0.198

1.07 (0.46–2.51)

0.875

Nuclear grade

Grade 1–2

1 (ref)

 

1 (ref)

 

1 (ref)

 

1 (ref)

 

Grade 3–4

4.06 (2.72–6.06)

< .001

2.62 (1.73–3.98)

< .001

2.98 (2.35–3.78)

< .001

1.95 (1.50–2.53)

< .001

Sarcomatoid differentiation

Yes

6.37 (3.34–12.16)

< .001

  

4.60 (2.96–7.14)

< .001

1.72 (1.04–2.86)

0.036

Necrosis

Yes

3.85 (2.57–5.77)

< .001

  

2.72 (2.08–3.54)

< .001

1.44 (1.02–2.02)

0.039

Lymphovascular invasion

Yes

3.51 (2.11–5.83)

< .001

  

3.67 (2.70–4.99)

< .001

  

Capsular invasion

Yes

1.74 (1.20–2.51)

0.004

  

1.40 (1.12–1.77)

0.004

  
Back to article page